Breaking News

Ampio, Ascendia Partner to Support Clinical Development of OA-201

Ascendia will provide scale-up, GLP supply and method validation, culminating in cGMP manufacturing.

Ampio Pharmaceuticals, Inc., a biopharmaceutical company focused on development of a potential treatment for osteoarthritis, selected Ascendia Pharmaceuticals, Inc. to provide services to support the clinical development of OA-201, a novel therapeutic for the treatment of symptomatic osteoarthritis pain. OA-201 consists of a natural metabolite, formulated as an injectable small molecule product which has demonstrated an active reduction in pain and cartilage degradation in preclinical studies. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters